Results 1 - 25 from 57 for "antibiotice iasi"
-
Antibiotice Iasi Wants to Cross RON100M Profit Threshold in 2024
03.25.2024
Antibiotice Iasi, the biggest Romanian-held drug manufacturer, wants to reach RON104 million net profit in 2024, up 28% from 2023, in line with its income and expenses budget. more
-
Antibiotice Iasi Seeks To Pay Dividends Of RON31M From 2023 Profit
03.14.2024
Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) is summoning its shareholders to approve, among others, the distribution of RON31 million from the company's 2023 profit under the form of more
-
Antibiotice Iasi's Net Profit More Than Doubles YoY To RON80.7M In 2023
02.28.2024
Pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) ended 2023 with net profit of RON80.7 million, up 109.5% from 2022, and a turnover of RON600.8 million, up 7.2% on the year, in line with more
-
Antibiotice Iasi Launches New Vet Product Range
02.09.2024
Antibiotice Iasi, the largest Romanian-held pharma producer, is launching eight veterinary products in the range of nutritional supplements, complementing the company’s veterinary prescription more
-
Antibiotice Iasi Calls Shareholders To Approve Contracting RON35M Credit Facility From Banca Transilvania
01.25.2024
The Board of Directors of pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) announced in a stock market report on Thursday (Jan. 25, 2024) that it has called shareholders for a meeting on February more
-
Antibiotice Iasi Shares To Be Included In MSCI Indices Starting With 1st Trading Day Of Dec 2023
11.16.2023
The Bucharest Stock Exchange has announced Wednesday evening that the shares of Antibiotice (ATB.RO), the Romanian manufacturer of generic drugs, listed on the local capital market for 26 years, will more
-
Antibiotice Iasi Ends 9M 2023 with RON463.4M Turnover, Up 28%, RON76M Net Profit, More than Double the 9M 2022 Level
11.15.2023
Romanian state-owned pharma producer Antibiotice Iasi for the first nine months of 2023 reported RON463.4 million turnover, up 28%, and RON76 million net profit, more than doubled the RON30 million more
-
Antibiotice Iasi Shareholders OK EUR25M Funding from EIB
10.31.2023
The extraordinary general meeting of shareholders convened by drug maker Antibiotice Iasi on October 30 approved the signing of a financing contract worth EUR25 million euro, i.e. RON23 million more
-
Antibiotice Iasi Looks at New Export Markets
10.05.2023
Antibiotic Iasi, the biggest Romanian-held drug producer, is mulling new export markets, including Nordic ones, where it is trying to already develop its first local partnerships. more
-
Antibiotice Iasi Calls Shareholders To Approve EUR25M Financing Contract With The Romanian State
09.16.2023
Romanian state-owned pharmaceutical manufacturer Antibiotice (ATB.RO) has called shareholders for a general meeting on October 30, 2023 to secure approval for the conclusion of a financing contract more
-
SIF Oltenia Buys 2.4% Of Antibiotice Iasi Shares In RON9.3M Deal
05.18.2023
Antibiotice Iasi (ATB.RO), Romania’s most important generic drug manufacturer, on Thursday (May 18) informed the Bucharest Stock Exchange (BVB) that SIF Oltenia (SIF5.RO), its second largest more
-
Antibiotice Iasi Posts RON178M Sales in 1Q/2023, Up around 40%, Sees Net Profit Almost Triple To RON22M
05.12.2023
Romanian pharma producer Antibiotice Iasi ended the first quarter of 203 with RON178 million sales, up around 40%, and RON22 million net profit, almost triple the level of the year-earlier period. more
-
Antibiotice Iasi Ends 2022 With RON38.5M Net Profit, Up 29% YoY
02.27.2023
Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Monday (Feb 27) that it ended 2022 with a net profit of RON38.5 million in 2022. up 28.6% versus 2021, more
-
Antibiotice Iasi Aims for RON580M Turnover and RON42M Profit in 2023
01.18.2023
Romanian pharmaceutical producer Antibiotice Iasi has budgeted RON580 million revenues for 2023, up 11% year-on-year and RON42 million net profit, 10% higher than in 2022. more
-
Enel X Romania To Build Solar Park For Antibiotice Iasi
12.13.2022
Enel X Romania, part of Enel X Global Retail, the advanced energy services division of Italy’s Enel Group, will build a photovoltaic (PV) park with a total installed capacity of 2.5 MW for Romanian more
-
Antibiotice Iasi Opens New Plant in Wake of EUR20M Investment
12.09.2022
Romanian pharmaceutical manufacturer Antibiotice Iasi is opening a new plant, in the wake of a EUR20 million investment, with a 50% higher production capacity than the existing unit. more
-
Antibiotice Iasi Revenue Up 47% YoY To RON361.7M In Jan-Sept 2022
11.11.2022
Romanian pharmaceutical manufacturer Antibiotice Iasi (ATB.RO) said in a stock market report on Friday that it ended the first nine months of 2022 with sales revenue of RON361.7 million, up 47% on the more
-
Antibiotice Iasi Plans to Invest RON300M in Coming Years
10.06.2022
Romanian drug maker Antibiotice Iasi has budgeted RON300 million investments for the following years. more
-
Antibiotice Iasi Net Profit Spikes 114% YoY To RON8.6M In 1Q/2022
05.13.2022
Antibiotice Iasi (ATB.RO), the biggest Romanian-held drug maker, reported a net profit net of RON8.6 million for the first three months of 2022, up 113.7% from the year-earlier period, in line with more
-
Antibiotice Iasi Eyes RON448M Revenues and RON32M Net Profit in 2022
01.31.2022
Antibiotice Iasi (ATB.RO), the biggest local Romanian-held drug producer, projects total revenues worth RON448 million in 2022, up 15% on the year and net profit of RON32 million, 6% higher than in more
-
Antibiotice Iasi Wants 60% of Sales to Come From Abroad by 2028
12.10.2021
Antibiotice Iasi, the biggest local Romanian-held drug maker, aims for exports to weigh 50%-60% in turnover by 2028. more
-
Antibiotice Iasi Turnover Up 10% To RON161M, Net Profit Up Nearly 1% To RON19.3M In 1H/2021
07.26.2021
Antibiotice Iasi (ATB.RO), the largest Romanian-held pharmaceutical producer, reported sales of RON161.4 million in the first half of 2021, up 10.2% from the same period in 2020, per calculations by more
-
Antibiotice Iasi 1Q Sales Drop 10% To RON66M, Net Profit Of RON4.03M, Close To Level In Year-Earlier Period
05.12.2021
Antibiotice Iasi (ATB.RO), the largest Romanian-held pharmaceutical producer, on Wednesday reported sales of RON66.1 million for the first quarter of 2021, down 10.2% on the year, and a net profit of more
-
Antibiotice Iasi Shareholders Approve RON2.22M Dividends From 2020 Profit, At 0.6% Yield
04.21.2021
Shareholders of state-run Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, on Wednesday approved the distribution of dividends worth RON2.2 million from the 2020 profit, more
-
SIF Oltenia Reaches 23% Ownership In Antibiotice Iasi
04.14.2021
Romanian state-owned Antibiotice Iasi (ATB.RO), the largest pharmaceutical producer in Romania, said in a stock market report on Wednesday that regional investment fund SIF Oltenia (SIF5.RO) reached more